Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nivolumab

nivolumab

49 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of nivolumab

285 trials tracked of nivolumab: 50 in phase 3 or 4 and 35 with published results. The most-cited published study has 3724 citations.

285Trials tracked
50Phase 3 & 4
0Recruiting
35With published results
Phase distribution
Phase 4 4 Phase 3 46 Phase 2 207 Phase 1 25 Other / NA 3
  1. Phase 3 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) Completed · 3,724 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,857 cited
  3. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,575 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer Completed · 1,769 cited
  5. Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Completed · 1,473 cited
  6. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,372 cited
Show 44 more trials
  1. Phase 3 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed · 1,242 cited
  2. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,204 cited
  3. Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Completed · 1,199 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Completed · 1,099 cited
  5. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 803 cited
  6. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) Completed · 662 cited
  7. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 513 cited
  8. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 498 cited
  9. Phase 3 Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer Completed · 362 cited
  10. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 268 cited
  11. Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Completed · 263 cited
  12. Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Completed · 241 cited
  13. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 220 cited
  14. Phase 3 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Completed · 187 cited
  15. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 182 cited
  16. Phase 3 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Completed · 179 cited
  17. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma Completed · 165 cited
  18. Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed · 159 cited
  19. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 155 cited
  20. Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Completed · 140 cited
  21. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 100 cited
  22. Phase 3 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Completed · 72 cited
  23. Phase 3 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread Completed · 69 cited
  24. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 43 cited
  25. Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma Completed · 32 cited
  26. Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed · 25 cited
  27. Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 23 cited
  28. Phase 3 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Completed · 2 cited
  29. Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma Completed
  30. Phase 4 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Completed
  31. Phase 4 Study of Nivolumab for Advanced Cancers in India Completed
  32. Phase 4 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India Completed
  33. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  34. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  35. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  36. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
  37. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Completed
  38. Phase 3 Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed
  39. Phase 3 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Completed
  40. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  41. Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  42. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  43. Phase 3 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Completed
  44. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC Completed

Showing the 50 most-cited and recently-updated of 285 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Songjiao Dihuang Tang for Immune Checkpoint Inhibitor-Associated Myocarditis: Trial Protocol
Drug Pipeline RCT
Songjiao Dihuang Tang for Immune Checkpoint Inhibitor-Associated Myocarditis: Trial Protocol Chinese herbal formula tested for immunotherapy heart side effect
This protocol describes a multicenter, double-blind RCT of Songjiao Dihuang Tang plus standard care vs placebo in 200 patients with mild ICI…
A new trial will test if a traditional Chinese herbal formula can protect cancer patients from a rare but serious heart complication caused …
Frontiers May 16, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Allergy & Immunology Meta-analysis
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Frontiers May 14, 2026
Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
Allergy & Immunology Meta-analysis
Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer New analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth
This meta-analysis evaluates dual immune checkpoint inhibitor therapy versus control treatments in patients with advanced or metastatic non-…
A large review of 6,369 patients found that using two immune checkpoint drugs together improved survival time compared to standard treatment…
Frontiers May 12, 2026
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Oncology Meta-analysis
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Frontiers May 7, 2026
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
Oncology Meta-analysis
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
May 5, 2026
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Pulmonology & Critical Care Meta-analysis
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
May 1, 2026
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
Pulmonology & Critical Care Meta-analysis
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
May 1, 2026
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
Allergy & Immunology Cohort
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers New Drug Combo Shows Strong Results for Advanced Bladder Cancer
This retrospective cohort study evaluated disitamab vedotin combined with a PD-1 inhibitor in 132 patients with locally advanced or metastat…
A new drug pairing shrank tumors in 71% of advanced bladder cancer patients, even those with diabetes or kidney problems.
Frontiers Apr 29, 2026
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
Oncology Meta-analysis
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Frontiers Apr 27, 2026
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors
Oncology RCT
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors A Tiny Dose of This Cancer Drug Is Outperforming Chemo
This Phase III randomized trial evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors prog…
Giving a much smaller dose of a powerful cancer drug can extend life with fewer side effects, making treatment more tolerable and accessible…
Apr 23, 2026
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial
Oncology RCT
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial New Combo Shows Modest Promise for Hard-to-Treat Neuroendocrine Cancers
This randomized phase II trial enrolled 185 patients with advanced neuroendocrine carcinoma refractory to platinum-based chemotherapy.
For patients with rare, aggressive neuroendocrine cancers that resist initial treatment, this study offers a new, though modest, combination…
Apr 23, 2026